Tuesday, 24 October 2017

ECTRIMS2017 Is Here! What do you want us to report on?




The Programme (UK)/Program (US) is online (CLICK HERE) The abstracts are now live



Come and see us at the Google Hangout 15.45-16.45 Central European Summer Time = GMT + 2 h) with NDG and ProfB your hosts to answer your questions and to report on what's "Hot" and What's "Not"....OK, they won't waste their time, and your time, with the what's not :-).

If you miss the Hangout some of us can be found on the ClinicSpeak and DigestingScience stands. 

37 comments:

  1. I believe I saw some courses pregnancy and lactation. I am interested in the suggested guidelines.

    ReplyDelete
  2. Can you please look out for anything on hand function? #ThinkHand

    ReplyDelete
  3. This:
    Immunology of MS: how does the pathogenic adaptive immune response
    develop?
    R. Liblau (Toulouse, FR)

    Immunology of MS: innate and adaptive immune events within the CNS
    F. Zipp (Mainz, DE)

    New spinal cord and infratentorial lesions in early relapse-onset MS are
    predictive of secondary progressive disease course after 15 years
    W.J. Brownlee (London, UK)

    Temporal variability profile of serum neurofilament light levels in
    multiple sclerosis patients

    Antigen expression by endothelial cells of the blood brain barrier elicits
    activation and pathogenicity of CD8 T cells in the central nervous system
    C. Meyer (Toulouse, FR)

    Unexpected role of neutrophil granulocytes during both murine and
    human central nervous system autoimmunity
    B. Knier (München, DE

    ReplyDelete
  4. I'd like to know what hsct discussion there is. Given its explosion over last year.

    ReplyDelete
  5. Anything novel on cognition (from descriptive to prescriptive) would be extremely of interest to me. HF!

    ReplyDelete
  6. Longitudinal studies? Maybe a little over done but, more and more clear information on how people are doing 10-20 years on helps.

    ReplyDelete
  7. Doesn't look like there's anything on HSCT at all. Great - sure the most effective MS intervention in decades not being discussed is really helpful and rewarding.

    http://www.professionalabstracts.com/ectrims2017/iplanner/#/grid

    ReplyDelete
    Replies
    1. I agree, does this say that ECTRIMS is a facade for marketing pharma drugs?

      Delete
    2. That goes without saying. Research in multiple sclerosis and yet nothing on stem cell therapy? No updates on clinical trials???

      Delete
    3. The first stem cell therapy to go in phase 3 for ALS. If it works in ALS, Then is guaranteed to work on MS. Also similar trial is in phase 2 in New York for MS.

      https://www.prnewswire.com/news-releases/brainstorm-enrolls-first-patients-in-phase-3-trial-of-nurown-in-als-300536911.html

      Delete
    4. If it works in ALS is a very, very big if, lets see what happens.

      Delete
    5. Thanks MouseDoctor2. Can't we just live in fools paradise a little longer? Besides. There must of been some indication it will work after phase 2 to proceed to 3? But your probably right. At best will be a modest affect. But let's see. If it works it will be dawn of a new age in medicine. Ultimately eradicating all diseases.

      Delete
    6. I don't want be be a wet blanket but also don't want to raise false hopes either. I really hope it does something, both my grandfather and aunt died of ALS.

      Delete
    7. So nothing in HSCT in parisms2017 - seriously, can you not see the gaping injustice and lack of care that the scientific and medical community has for pwMS?

      It's just a self congratulatory club making faux progress in to a deviststing disease that HSCT has been highly effective in stopping.

      Delete
    8. We agree, it's a glaring omission but if those who are doing HSCT for MS don't submit their work for presentation at the meeting then the organisers hands are tied.

      Delete
    9. "those who are doing HSCT for MS don't submit their work for presentation at the meeting"

      Appareantly they did....(you did´nt look hard enough)... :)

      https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199908/andreas.tolf.corpus.callosum.atrophy.in.ms.is.halted.by.autologous.html?f=media=3

      And look ,it even treats those cases of Natalizumab Cns Lymphona

      https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199780/agns.fromont.favorable.evolution.post.hematologous.stem.cell.transplant.after.html?f=media=3


      Obrigado

      Delete
  8. Thanks... I liked the look of these:

    234 - Aerobic exercise induces functional and structural reorganisation an rct

    230 - ECTRIMS-EAN guideline

    195 - Multiple sclerosis disease course prediction: machine learning

    P1244 - calorie restricted diets

    P1239 - trial design in progressive ms

    ReplyDelete
  9. I am interested in anything Pediatric MS related.
    I do the yearly reporting back to the Pediatric Multiple Sclerosis Alliance of ECTRIMS/ACTRIMS as best I can, based on posted abstracts, videos, blogs, etc coming out of the conferences.

    ReplyDelete
  10. Thanks for making me chuckle MD2😃

    ReplyDelete
  11. How expensive is the beer

    Best Dmt ever

    Lollllllllllllllllll

    ReplyDelete
  12. Is ibudalist a hit or miss? Seems like a boring ECTRIMS this year. Any head turning breakthroughs or data realised that turn understanding of MS upside down?

    ReplyDelete
    Replies
    1. Ooops ibudalist shows positive results. If I remember correctly barts team thought it wouldn't work. Spinimod also had low expectations last given the failure of fingolimod in ppms. Hate to say it and with taking anything away from the excellent research done by barts. But does it not prove understanding of MS is not complete or correct?

      Delete
  13. Please can you give a comment/explanation on how fingolimod appears long-term (conversion to SPMS) less affective comparing to injectables.

    ... "The risk (assessed as hazard ratios) to convert to SPMS among patients treated with injectables was 0.31 (follow-up of 7.9 years), 0.23 with Gilenya (follow-up 4.6 years), 0.50 with Tysabri (follow-up 4.9 years), and 0.60 with Lemtrada (follow-up 7.2 years), compared to matched untreated patients. ...
    (MSParis2017 – Lemtrada and Tysabri More Efficient Than Older Injectables in Preventing SPMS Onset, Study https://multiplesclerosisnewstoday.com/2017/10/26/msparis2017-lemtrada-and-tysabri-more-efficient-than-older-injectables-in-preventing-spms-onset/)

    ReplyDelete
  14. A Mouse Doc from Portugal

    Filipe Palavra

    Ectrims 2017

    https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199480/filipe.palavra.is.dpp4.glp-1.pathway.a.possible.target.for.remyelination.a.html?f=menu=6*ce_id=1278*ot_id=18222*media=3

    Wonder if Monica knows about it

    Obrigado

    ReplyDelete
  15. A little help for the "black snaw"?

    Leukocyte repopulation following alemtuzumab treatment in relapsing-remitting MS contains multiple regulatory immune cell types

    https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/200634/wendy.gilmore.leukocyte.repopulation.following.alemtuzumab.treatment.in.html?f=menu=6*ce_id=1278*ot_id=18224*media=3

    Is this another way of reporting what you allready know?

    Funny they mentioning the memory b cells a Bregs (never heard that before)

    Obrigado

    ReplyDelete
  16. Should say "didn´t mentioning the memory b cell"

    ReplyDelete
    Replies
    1. But they showed very clearly that b memory's were depleted, on the poster. Some of the subpopulations were blind faith on the gating

      Delete
    2. You right

      "memory B cells dropped to minimal levels by M5 and remained reduced"

      Sorry

      Obrigado

      Delete
  17. What about GNbAC1? The Phase IIb trial results seem encouraging at the 6 Month mark..

    http://www.geneuro.com/data/news/GeNeuro-CHANGE-MS-6m-Data-Presentation-MSParis2017-ENG.pdf

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.